PL1940786T3 - Pochodne bifenylowe i ich zastosowanie w leczeniu zapalenia wątroby typu C - Google Patents
Pochodne bifenylowe i ich zastosowanie w leczeniu zapalenia wątroby typu CInfo
- Publication number
- PL1940786T3 PL1940786T3 PL06779478T PL06779478T PL1940786T3 PL 1940786 T3 PL1940786 T3 PL 1940786T3 PL 06779478 T PL06779478 T PL 06779478T PL 06779478 T PL06779478 T PL 06779478T PL 1940786 T3 PL1940786 T3 PL 1940786T3
- Authority
- PL
- Poland
- Prior art keywords
- treating hepatitis
- biphenyl derivatives
- hepatitis
- biphenyl
- derivatives
- Prior art date
Links
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical class C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 title abstract 2
- 208000006454 hepatitis Diseases 0.000 title 1
- 231100000283 hepatitis Toxicity 0.000 title 1
- 208000005176 Hepatitis C Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
- C07D237/28—Cinnolines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
- C07D279/12—1,4-Thiazines; Hydrogenated 1,4-thiazines not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
- C07D295/26—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
- C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Indole Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Furan Compounds (AREA)
- Pyridine Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0518971.7A GB0518971D0 (en) | 2005-09-16 | 2005-09-16 | Chemical compounds |
| GB0610664A GB0610664D0 (en) | 2006-05-30 | 2006-05-30 | Chemical compounds |
| GB0610663A GB0610663D0 (en) | 2006-05-30 | 2006-05-30 | Chemical compounds |
| PCT/GB2006/003469 WO2007031791A1 (en) | 2005-09-16 | 2006-09-18 | Biphenyl derivatives and their use in treating hepatitis c |
| EP06779478A EP1940786B1 (en) | 2005-09-16 | 2006-09-18 | Biphenyl derivatives and their use in treating hepatitis c |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL1940786T3 true PL1940786T3 (pl) | 2010-12-31 |
Family
ID=37398704
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL06779478T PL1940786T3 (pl) | 2005-09-16 | 2006-09-18 | Pochodne bifenylowe i ich zastosowanie w leczeniu zapalenia wątroby typu C |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US8008303B2 (pl) |
| EP (1) | EP1940786B1 (pl) |
| JP (1) | JP2009508835A (pl) |
| KR (1) | KR20080050490A (pl) |
| AT (1) | ATE478044T1 (pl) |
| AU (2) | AU2006290442B2 (pl) |
| BR (1) | BRPI0615934A2 (pl) |
| CA (1) | CA2621364A1 (pl) |
| CY (1) | CY1110835T1 (pl) |
| DE (1) | DE602006016313D1 (pl) |
| DK (1) | DK1940786T3 (pl) |
| EC (1) | ECSP088367A (pl) |
| ES (1) | ES2348332T3 (pl) |
| HK (1) | HK1121440A1 (pl) |
| HR (1) | HRP20100542T1 (pl) |
| IL (1) | IL189694A0 (pl) |
| NO (1) | NO20081846L (pl) |
| NZ (1) | NZ566276A (pl) |
| PL (1) | PL1940786T3 (pl) |
| PT (1) | PT1940786E (pl) |
| RS (1) | RS51470B (pl) |
| SI (1) | SI1940786T1 (pl) |
| WO (1) | WO2007031791A1 (pl) |
Families Citing this family (94)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA93548C2 (uk) * | 2006-05-05 | 2011-02-25 | Айерем Елелсі | Сполуки та композиції як модулятори хеджхогівського сигнального шляху |
| US8633175B2 (en) | 2006-08-09 | 2014-01-21 | Glaxosmithkline Llc | Compounds as antagonists or inverse agonists at opioid receptors |
| US7659270B2 (en) | 2006-08-11 | 2010-02-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7759495B2 (en) * | 2006-08-11 | 2010-07-20 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8303944B2 (en) | 2006-08-11 | 2012-11-06 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7745636B2 (en) | 2006-08-11 | 2010-06-29 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8329159B2 (en) | 2006-08-11 | 2012-12-11 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| WO2008028937A1 (en) * | 2006-09-08 | 2008-03-13 | Novartis Ag | N-biaryl (hetero) arylsulphonamide derivatives useful in the treatment of diseases mediated by lymphocytes interactions |
| US7741347B2 (en) | 2007-05-17 | 2010-06-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7728027B2 (en) | 2007-08-08 | 2010-06-01 | Bristol-Myers Squibb Company | Process for synthesizing compounds useful for treating hepatitis C |
| US8629171B2 (en) | 2007-08-08 | 2014-01-14 | Bristol-Myers Squibb Company | Crystalline form of methyl ((1S)-1-((25)-2-(5-(4'-(2-((25)-1((2S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate dihydrochloride salt |
| WO2009034390A1 (en) * | 2007-09-14 | 2009-03-19 | Arrow Therapeutics Limited | Heterocyclic derivatives and their use in treating hepatitis c |
| AU2009214977A1 (en) | 2008-02-12 | 2009-08-20 | Bristol-Myers Squibb Company | Heterocyclic derivatives as hepatitis C virus inhibitors |
| US7704992B2 (en) * | 2008-02-13 | 2010-04-27 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8147818B2 (en) | 2008-02-13 | 2012-04-03 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7906655B2 (en) | 2008-08-07 | 2011-03-15 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| DE102008049675A1 (de) | 2008-09-30 | 2010-04-01 | Markus Dr. Heinrich | Verfahren zur Herstellung von 3-Aminobiphenylen |
| US8383094B2 (en) | 2008-10-01 | 2013-02-26 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8394968B2 (en) | 2009-02-17 | 2013-03-12 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| TWI438200B (zh) | 2009-02-17 | 2014-05-21 | 必治妥美雅史谷比公司 | Ｃ型肝炎病毒抑制劑 |
| WO2010094977A1 (en) * | 2009-02-23 | 2010-08-26 | Arrow Therapeutics Limited | Novel biphenyl compounds useful for the treatment of hepatitis c |
| MX2011008982A (es) | 2009-02-27 | 2011-09-15 | Enata Pharmaceuticals Inc | Inhibidores del virus de la hepatitis c. |
| US8796466B2 (en) | 2009-03-30 | 2014-08-05 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| TW201038559A (en) | 2009-04-09 | 2010-11-01 | Bristol Myers Squibb Co | Hepatitis C virus inhibitors |
| US8143414B2 (en) | 2009-04-13 | 2012-03-27 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8138215B2 (en) | 2009-05-29 | 2012-03-20 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8211928B2 (en) | 2009-05-29 | 2012-07-03 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| EP2475254A4 (en) * | 2009-09-11 | 2013-05-22 | Enanta Pharm Inc | HEPATITIS C-VIRUS HEMMER |
| US20110269956A1 (en) | 2009-11-11 | 2011-11-03 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| US20110274648A1 (en) | 2009-11-11 | 2011-11-10 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| US20110281910A1 (en) | 2009-11-12 | 2011-11-17 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| EP2512480A4 (en) | 2009-12-14 | 2013-05-15 | Enanta Pharm Inc | HEPATITIS C-VIRUS HEMMER |
| US8377980B2 (en) | 2009-12-16 | 2013-02-19 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US9452980B2 (en) | 2009-12-22 | 2016-09-27 | Hoffmann-La Roche Inc. | Substituted benzamides |
| US8362020B2 (en) | 2009-12-30 | 2013-01-29 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8754219B2 (en) * | 2010-04-27 | 2014-06-17 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
| JPWO2012008435A1 (ja) * | 2010-07-13 | 2013-09-09 | 大日本住友製薬株式会社 | ビアリールアミド誘導体またはその薬理学的に許容される塩 |
| US8921372B2 (en) * | 2010-11-04 | 2014-12-30 | Theravance Biopharma R&D Ip, Llc | Inhibitors of hepatitis C virus |
| US8552047B2 (en) | 2011-02-07 | 2013-10-08 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| RU2456266C1 (ru) * | 2011-04-06 | 2012-07-20 | Максим Эдуардович Запольский | Производные 4,4'-бифениламидов, обладающие фармакологической активностью, и лекарственные средства на их основе |
| US9546160B2 (en) | 2011-05-12 | 2017-01-17 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| KR20140079386A (ko) * | 2011-08-31 | 2014-06-26 | 아마켐 엔브이 | 신규한 rock 키나아제 억제제 |
| WO2013030750A1 (en) | 2011-09-01 | 2013-03-07 | Lupin Limited | Antiviral compounds |
| MX347692B (es) * | 2011-11-03 | 2017-05-09 | Theravance Inc | Inhibidores del virus de la hepatitis c. |
| CA2857344C (en) | 2011-12-21 | 2019-02-12 | Novira Therapeutics, Inc. | Hepatitis b antiviral agents |
| US9326973B2 (en) | 2012-01-13 | 2016-05-03 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| WO2013118097A1 (en) | 2012-02-10 | 2013-08-15 | Lupin Limited | Antiviral compounds with a dibenzooxaheterocycle moiety |
| WO2013130892A1 (en) | 2012-03-02 | 2013-09-06 | Anayaderm, Inc. | Liver x receptor (lxr) modulators for the treatment of dermal diseases, disorders and conditions |
| TW201414704A (zh) * | 2012-07-02 | 2014-04-16 | Biogen Idec Inc | 作爲ＲＯＲ－γ受體之反向促效劑之含聯芳化合物 |
| SG11201501362PA (en) | 2012-08-28 | 2015-03-30 | Janssen Sciences Ireland Uc | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b |
| CA2899706C (en) | 2013-02-28 | 2021-10-19 | Janssen Sciences Ireland Uc | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b |
| US8993771B2 (en) | 2013-03-12 | 2015-03-31 | Novira Therapeutics, Inc. | Hepatitis B antiviral agents |
| CN105579457B (zh) | 2013-03-20 | 2017-08-04 | 拜耳制药股份公司 | 取代的n‑联苯‑3‑乙酰基氨基‑苯甲酰胺和n‑[3‑(乙酰基氨基)苯基]‑联苯‑甲酰胺及其作为wnt信号通路抑制剂用途 |
| WO2014161888A1 (en) | 2013-04-03 | 2014-10-09 | Janssen R&D Ireland | N-phenyl-carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b |
| JO3603B1 (ar) | 2013-05-17 | 2020-07-05 | Janssen Sciences Ireland Uc | مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي |
| US9717712B2 (en) | 2013-07-02 | 2017-08-01 | Bristol-Myers Squibb Company | Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus |
| US20150023913A1 (en) | 2013-07-02 | 2015-01-22 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| EP3021845A1 (en) | 2013-07-17 | 2016-05-25 | Bristol-Myers Squibb Company | Combinations comprising biphenyl derivatives for use in the treatment of hcv |
| EP3357906B1 (en) | 2013-07-25 | 2019-12-04 | Janssen Sciences Ireland Unlimited Company | Glyoxamide substituted pyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b |
| CA2923175C (en) | 2013-09-04 | 2022-07-26 | Alexar Therapeutics, Inc. | Liver x receptor (lxr) modulators |
| EP3041834A4 (en) | 2013-09-04 | 2017-01-18 | Ralexar Therapeutics, Inc. | Liver x receptor (lxr) modulators |
| US9567299B2 (en) | 2013-10-23 | 2017-02-14 | Janssen Sciences Ireland Uc | Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
| CN104725365B (zh) * | 2013-12-23 | 2019-02-26 | 南京圣和药业股份有限公司 | 丙型肝炎病毒抑制剂及其应用 |
| US10392349B2 (en) | 2014-01-16 | 2019-08-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
| US9181288B2 (en) | 2014-01-16 | 2015-11-10 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
| US9169212B2 (en) | 2014-01-16 | 2015-10-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
| AU2015214096B2 (en) | 2014-02-05 | 2021-02-11 | Novira Therapeutics, Inc. | Combination therapy for treatment of HBV infections |
| DK3102572T3 (en) | 2014-02-06 | 2019-02-04 | Janssen Sciences Ireland Uc | SULFAMOYLPYRROLAMIDE DERIVATIVES AND THEIR USE AS MEDICINES TO TREAT HEPATITIS B |
| US9400280B2 (en) | 2014-03-27 | 2016-07-26 | Novira Therapeutics, Inc. | Piperidine derivatives and methods of treating hepatitis B infections |
| JP2018507212A (ja) | 2015-02-20 | 2018-03-15 | バイエル・ファルマ・アクティエンゲゼルシャフト | Ｎ−フェニル−（モルホリン−４−イルまたはピペラジニル）アセトアミド誘導体およびｗｎｔシグナル伝達経路の阻害剤としてのその使用 |
| WO2016149581A1 (en) | 2015-03-19 | 2016-09-22 | Novira Therapeutics, Inc. | Azocane and azonane derivatives and methods of treating hepatitis b infections |
| US10875876B2 (en) | 2015-07-02 | 2020-12-29 | Janssen Sciences Ireland Uc | Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
| US10617675B2 (en) | 2015-08-06 | 2020-04-14 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US10077239B2 (en) | 2015-09-29 | 2018-09-18 | Novira Therapeutics, Inc. | Crystalline forms of a hepatitis B antiviral agent |
| MX377836B (es) | 2016-03-17 | 2025-03-11 | F Hoffmann La Roche Ag | Derivado de 5-etil-4-metil-pirazol-3-carboxamida teniendo actividad como agonista de receptor asociado con aminas trazas (taar). |
| KR20180129943A (ko) | 2016-04-15 | 2018-12-05 | 노비라 테라퓨틱스, 인코포레이티드 | 캡시드 조립 억제제를 포함하는 배합물 및 방법 |
| EP3455218A4 (en) | 2016-05-10 | 2019-12-18 | C4 Therapeutics, Inc. | C3 CARBON-BASED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION |
| EP3455219A4 (en) | 2016-05-10 | 2019-12-18 | C4 Therapeutics, Inc. | AMINE-RELATED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION |
| JOP20190024A1 (ar) | 2016-08-26 | 2019-02-19 | Gilead Sciences Inc | مركبات بيروليزين بها استبدال واستخداماتها |
| EP3641762A4 (en) | 2017-06-20 | 2021-03-10 | C4 Therapeutics, Inc. | N / O BONDED DEGRONS AND DEGRONIMERS FOR PROTEIN DEGRADATION |
| CN111372585A (zh) | 2017-11-16 | 2020-07-03 | C4医药公司 | 用于靶蛋白降解的降解剂和降解决定子 |
| CN111788204B (zh) | 2018-02-26 | 2023-05-05 | 吉利德科学公司 | 作为hbv复制抑制剂的取代吡咯嗪化合物 |
| MA52019A (fr) | 2018-03-14 | 2021-01-20 | Janssen Sciences Ireland Unlimited Co | Schéma posologique de modulateur d'assemblage de capside |
| KR20210098504A (ko) | 2018-12-04 | 2021-08-10 | 브리스톨-마이어스 스큅 컴퍼니 | 다중 동위원소체 반응 모니터링에 의한 샘플내 보정 곡선을 사용한 분석 방법 |
| TW202045499A (zh) | 2019-02-22 | 2020-12-16 | 愛爾蘭商健生科學愛爾蘭無限公司 | 用於治療ｈｂｖ感染或ｈｂｖ誘發疾病之醯胺衍生物 |
| AU2020269897A1 (en) | 2019-05-06 | 2021-10-14 | Janssen Sciences Ireland Unlimited Company | Amide derivatives useful in the treatment of HBV infection or HBV-induced diseases |
| PE20221040A1 (es) | 2019-10-25 | 2022-06-17 | Gilead Sciences Inc | Compuestos moduladores de glp-1r |
| US12121511B2 (en) | 2020-01-29 | 2024-10-22 | Gilead Sciences, Inc. | GLP-1R modulating compounds |
| EP4247804A1 (en) | 2020-11-20 | 2023-09-27 | Gilead Sciences, Inc. | Polyheterocyclic glp-1 r modulating compounds |
| EP4304711A1 (en) | 2021-03-11 | 2024-01-17 | Gilead Sciences, Inc. | Glp-1r modulating compounds |
| EP4304712A1 (en) | 2021-03-11 | 2024-01-17 | Gilead Sciences, Inc. | Glp-1r modulating compounds |
| EP4271672A1 (en) | 2021-04-21 | 2023-11-08 | Gilead Sciences, Inc. | Carboxy-benzimidazole glp-1r modulating compounds |
| EP4479380A1 (en) * | 2022-02-18 | 2024-12-25 | Accent Therapeutics, Inc. | Inhibitors of rna helicase dhx9 and uses thereof |
| WO2023212718A2 (en) * | 2022-04-29 | 2023-11-02 | Cornell University | Methods of treating a virus infection and methods of inhibiting viral replication |
Family Cites Families (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5026940A (en) * | 1989-09-08 | 1991-06-25 | Catalytica, Inc. | Manufacture of 4,4'-diisopropylbiphenyl |
| GB9119920D0 (en) * | 1991-09-18 | 1991-10-30 | Glaxo Group Ltd | Chemical compounds |
| US5605919A (en) | 1993-02-26 | 1997-02-25 | Takeda Chemical Industries, Ltd. | Treatment for viral diseases |
| HUT73813A (en) | 1993-06-30 | 1996-09-30 | Wellcome Found | Anti-athero-sclerotic diaryl compounds, process to prepare them and pharmaceutical compositions contg. them |
| IL117580A0 (en) | 1995-03-29 | 1996-07-23 | Merck & Co Inc | Inhibitors of farnesyl-protein transferase and pharmaceutical compositions containing them |
| CA2250587A1 (en) | 1996-04-03 | 1997-10-09 | Christopher J. Dinsmore | Inhibitors of farnesyl-protein transferase |
| US6297239B1 (en) | 1997-10-08 | 2001-10-02 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
| US6403595B1 (en) | 1998-02-05 | 2002-06-11 | Takeda Chemical Industries, Ltd. | Sulfonamide derivatives, processes for producing the same and utilization thereof |
| US6586475B1 (en) | 1998-11-20 | 2003-07-01 | Takeda Chemical Industries, Ltd. | β-amyloid protein production/secretion inhibitors |
| AUPP818099A0 (en) | 1999-01-14 | 1999-02-11 | Fujisawa Pharmaceutical Co., Ltd. | New n-containing heterocyclic compounds |
| WO2001019788A2 (en) | 1999-09-17 | 2001-03-22 | Cor Therapeutics, Inc. | BENZAMIDES AND RELATED INHIBITORS OF FACTOR Xa |
| WO2001021577A2 (en) | 1999-09-20 | 2001-03-29 | Takeda Chemical Industries, Ltd. | Melanin concentrating hormone antagonist |
| WO2001064643A2 (en) | 2000-02-29 | 2001-09-07 | Cor Therapeutics, Inc. | BENZAMIDES AND RELATED INHIBITORS OF FACTOR Xa |
| US6433236B1 (en) * | 2000-03-21 | 2002-08-13 | Arteva North America S.A.R.L. | Acid catalyzed isomerization of substituted diaryls |
| EP1295867A4 (en) * | 2000-06-28 | 2005-03-30 | Takeda Pharmaceutical | BIPHENYL COMPOUND |
| DE60229059D1 (de) | 2001-05-08 | 2008-11-06 | Univ Yale | Proteomimetische verbindungen und verfahren |
| EP1578898A2 (en) | 2001-07-13 | 2005-09-28 | Virtual Drug Development, Inc. | Nad synthetase inhibitors and uses thereof |
| EP1572072A4 (en) | 2001-09-13 | 2009-04-01 | Genesoft Inc | PROCESS FOR TREATING INFECTIONS WITH PHARMACORESISTANT BACTERIA |
| GB0124938D0 (en) * | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
| GB0124941D0 (en) * | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
| GB0124933D0 (en) * | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
| GB0124928D0 (en) * | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
| GB0124932D0 (en) * | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
| GB0124934D0 (en) * | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
| GB0124931D0 (en) * | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
| CA2473740A1 (en) | 2002-01-18 | 2003-07-31 | David Solow-Cordero | Methods of treating conditions associated with an edg receptor |
| CN100369898C (zh) | 2002-02-12 | 2008-02-20 | 史密丝克莱恩比彻姆公司 | 用作p38抑制剂的烟酰胺衍生物 |
| GB0209891D0 (en) * | 2002-04-30 | 2002-06-05 | Glaxo Group Ltd | Novel compounds |
| CA2487211C (en) * | 2002-06-04 | 2010-09-14 | Neogenesis Pharmaceuticals, Inc. | Pyrazolo(1,5a) pyrimidine compounds as antiviral agents |
| WO2004007472A1 (ja) * | 2002-07-10 | 2004-01-22 | Ono Pharmaceutical Co., Ltd. | Ｃｃｒ４アンタゴニストおよびその医薬用途 |
| EP2172460A1 (en) | 2002-11-01 | 2010-04-07 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of JAK and other protein kinases |
| US7122557B2 (en) | 2003-03-18 | 2006-10-17 | Bristol-Myers Squibb Company | Sulfonyl-amidino-containing and tetrahydropyrimidino-containing compounds as factor Xa inhibitors |
| CA2520763A1 (en) | 2003-04-03 | 2004-10-21 | The Regents Of The University Of California | Improved inhibitors for the soluble epoxide hydrolase |
| DE602004021573D1 (de) * | 2003-04-07 | 2009-07-30 | Pharmacyclics Inc | Hydroxamate als therapeutische mittel |
| GB0308185D0 (en) * | 2003-04-09 | 2003-05-14 | Smithkline Beecham Corp | Novel compounds |
| GB0308186D0 (en) * | 2003-04-09 | 2003-05-14 | Smithkline Beecham Corp | Novel compounds |
| DK1651232T3 (da) | 2003-07-23 | 2011-02-28 | Synta Pharmaceuticals Corp | Forbindelser mod inflammation og immunrelaterede anvendelser |
| DE602004017494D1 (de) * | 2003-07-25 | 2008-12-11 | Novartis Ag | Inhibitoren von p-38-kinase |
| US20050054691A1 (en) | 2003-08-29 | 2005-03-10 | St. Jude Children's Research Hospital | Carboxylesterase inhibitors |
| US7749999B2 (en) | 2003-09-11 | 2010-07-06 | Itherx Pharmaceuticals, Inc. | Alpha-ketoamides and derivatives thereof |
| EP1679309A4 (en) * | 2003-10-24 | 2007-03-28 | Ono Pharmaceutical Co | ANTISTRESS MEDICAMENT AND ITS MEDICAL USE |
| EP1709155B1 (en) | 2003-12-31 | 2013-10-02 | Chesterford Enterprises Limited | Compounds and compositions for treating dysproliferative diseases, and methods of use thereof |
| US7816367B2 (en) | 2004-02-27 | 2010-10-19 | Amgen Inc. | Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders |
| TW200600492A (en) * | 2004-05-18 | 2006-01-01 | Achillion Pharmaceuticals Inc | Substituted aryl acylthioureas and related compounds; inhibitors of viral replication |
| CN1956975A (zh) | 2004-05-21 | 2007-05-02 | 默克公司 | 趋化因子受体活性的氨基环戊基杂环和碳环调节剂 |
| US7381728B2 (en) * | 2004-07-28 | 2008-06-03 | Glaxo Group Limited | Piperazine derivatives useful for the treatment of gastrointestinal disorders |
| ZA200700811B (en) | 2004-08-06 | 2008-10-29 | Otsuka Pharma Co Ltd | Aromatic compound |
| CA2581489A1 (en) | 2004-10-06 | 2006-04-13 | Recepticon Aps | Use of compounds for the prevention of drug-induced cell toxicity |
| US7381732B2 (en) | 2004-10-26 | 2008-06-03 | Bristol-Myers Squibb Company | Pyrazolobenzamides and derivatives as factor Xa inhibitors |
| KR20070107022A (ko) * | 2005-01-07 | 2007-11-06 | 신타 파마슈티칼스 코프. | 염증 및 면역 관련 용도를 위한 화합물 |
| WO2006091858A1 (en) * | 2005-02-25 | 2006-08-31 | Rigel Pharmaceuticals, Inc. | Benzisothiazoles useful for treating or preventing hcv infection |
| CA2603589A1 (en) | 2005-04-01 | 2006-10-05 | Methylgene Inc. | Inhibitors of histone deacetylase |
| US20090176837A1 (en) | 2005-07-12 | 2009-07-09 | Sony Corporation | Compounds with activity at retinoic acid receptors |
| WO2007087441A2 (en) | 2006-01-25 | 2007-08-02 | Synta Pharmaceuticals Corp. | Substituted aromatic compounds for inflammation and immune-related uses |
| UY30117A1 (es) | 2006-01-31 | 2007-06-29 | Tanabe Seiyaku Co | Compuesto amina trisustituido |
| WO2007103162A2 (en) | 2006-03-01 | 2007-09-13 | Samaritan Pharmaceuticals, Inc. | Structure based drug design of steroidogenesis inhibitors |
| AU2007266915A1 (en) | 2006-05-30 | 2007-12-06 | Arrow Therapeutics Limited | Biphenyl derivatives and their use in treating hepatitis C |
| UA95978C2 (ru) | 2006-10-02 | 2011-09-26 | Оцука Фармас'Ютікел Ко., Лтд. | Ингибитор активации stat3/5 |
| US20080255155A1 (en) | 2006-10-18 | 2008-10-16 | Stephane Raeppel | Kinase inhibitors and uses thereof |
| AU2007333377B2 (en) | 2006-12-08 | 2014-01-16 | Millennium Pharmaceuticals, Inc. | Unit dose formulations and methods of treating thrombosis with an oral factor Xa inhibitor |
| WO2008092006A2 (en) | 2007-01-24 | 2008-07-31 | Cernofina, Llc | Antimicrobial compositions |
| WO2008147864A2 (en) | 2007-05-22 | 2008-12-04 | Xenon Pharmaceuticals Inc. | Methods of using piperazine compounds in treating sodium channel-mediated diseases or conditions |
| WO2009034390A1 (en) | 2007-09-14 | 2009-03-19 | Arrow Therapeutics Limited | Heterocyclic derivatives and their use in treating hepatitis c |
-
2006
- 2006-09-18 PL PL06779478T patent/PL1940786T3/pl unknown
- 2006-09-18 EP EP06779478A patent/EP1940786B1/en active Active
- 2006-09-18 DE DE602006016313T patent/DE602006016313D1/de active Active
- 2006-09-18 AU AU2006290442A patent/AU2006290442B2/en not_active Ceased
- 2006-09-18 SI SI200630798T patent/SI1940786T1/sl unknown
- 2006-09-18 BR BRPI0615934-6A patent/BRPI0615934A2/pt not_active IP Right Cessation
- 2006-09-18 AT AT06779478T patent/ATE478044T1/de active
- 2006-09-18 DK DK06779478.4T patent/DK1940786T3/da active
- 2006-09-18 RS RSP-2010/0437A patent/RS51470B/en unknown
- 2006-09-18 KR KR1020087008964A patent/KR20080050490A/ko not_active Application Discontinuation
- 2006-09-18 ES ES06779478T patent/ES2348332T3/es active Active
- 2006-09-18 CA CA002621364A patent/CA2621364A1/en not_active Abandoned
- 2006-09-18 PT PT06779478T patent/PT1940786E/pt unknown
- 2006-09-18 WO PCT/GB2006/003469 patent/WO2007031791A1/en active Application Filing
- 2006-09-18 NZ NZ566276A patent/NZ566276A/en unknown
- 2006-09-18 US US12/066,983 patent/US8008303B2/en not_active Expired - Fee Related
- 2006-09-18 JP JP2008530624A patent/JP2009508835A/ja active Pending
-
2008
- 2008-02-21 IL IL189694A patent/IL189694A0/en unknown
- 2008-04-14 EC EC2008008367A patent/ECSP088367A/es unknown
- 2008-04-16 NO NO20081846A patent/NO20081846L/no not_active Application Discontinuation
- 2008-11-24 HK HK08112854.2A patent/HK1121440A1/xx unknown
-
2010
- 2010-10-05 HR HR20100542T patent/HRP20100542T1/hr unknown
- 2010-10-14 CY CY20101100915T patent/CY1110835T1/el unknown
- 2010-10-29 AU AU2010238549A patent/AU2010238549A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| US20080255105A1 (en) | 2008-10-16 |
| PT1940786E (pt) | 2010-10-04 |
| HRP20100542T1 (hr) | 2010-11-30 |
| EP1940786A1 (en) | 2008-07-09 |
| RS51470B (en) | 2011-04-30 |
| KR20080050490A (ko) | 2008-06-05 |
| IL189694A0 (en) | 2008-06-05 |
| ATE478044T1 (de) | 2010-09-15 |
| NZ566276A (en) | 2011-03-31 |
| ES2348332T3 (es) | 2010-12-02 |
| EP1940786B1 (en) | 2010-08-18 |
| NO20081846L (no) | 2008-06-04 |
| SI1940786T1 (sl) | 2010-11-30 |
| CA2621364A1 (en) | 2007-03-22 |
| JP2009508835A (ja) | 2009-03-05 |
| AU2006290442B2 (en) | 2010-07-29 |
| AU2010238549A1 (en) | 2010-11-18 |
| HK1121440A1 (en) | 2009-04-24 |
| US8008303B2 (en) | 2011-08-30 |
| AU2006290442A1 (en) | 2007-03-22 |
| WO2007031791A1 (en) | 2007-03-22 |
| DK1940786T3 (da) | 2010-11-08 |
| DE602006016313D1 (de) | 2010-09-30 |
| ECSP088367A (es) | 2008-06-30 |
| CY1110835T1 (el) | 2015-06-10 |
| BRPI0615934A2 (pt) | 2011-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL189694A0 (en) | Biphenyl derivatives and their use in treating hepatitis c | |
| MY146111A (en) | Acylaminopyrazoles as fgfr inhibitors | |
| TW200738725A (en) | Unsaturated mTOR inhibitors | |
| TW200740776A (en) | N-phenylbenzotriazolyl c-kit inhibitors | |
| UA84712C2 (en) | N-substituted pyrazolyl-amidyl-benzimidazolyl c-kit inhibitors | |
| MY148688A (en) | 2-methylmorpholine pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mtor inhibitors | |
| JO2848B1 (en) | Organic compounds | |
| TW200801006A (en) | Fused bicyclic mTOR inhibitors | |
| GEP20084551B (en) | 4-phenylamino-quinazolin-6-yl-amides | |
| WO2005021544A3 (en) | N3-substituted imidazopyridine-derivatives as c-kit inhibitors | |
| GEP20105024B (en) | Fused heterocyclic compound | |
| HK1112910A1 (en) | Compounds and methods for the treatment or prevention of flavivirus infections | |
| GB0413087D0 (en) | Therapeutic compounds | |
| PL1919466T3 (pl) | Formulacje do leczenia nieprawidłowości lipoproteinowych obejmujące statynę i pochodną metylonikotynoamidu | |
| TW200800969A (en) | Compounds | |
| EP2639229A3 (en) | Thiazole Derivative and use thereof as VAP-1 Inhibitor | |
| IL191751A0 (en) | Pyrrolo[2,3-c]pyridine derivatives | |
| GEP20094638B (en) | Benzimidazolone carboxylic acid derivatives | |
| MX2010008226A (es) | Derivados de difluorobifenilamida para el tratamiento de hipertension ocular. | |
| PE20030061A1 (es) | 1-biaril-1,8-naftiridin-4-ona como inhibidores de fosfodiesterasa-4 | |
| UA96304C2 (en) | 2-METHYLMORPHOLINE PYRIDO-, PYRAZO- AND PYRIMIDO-PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | |
| UA96969C2 (en) | Acylaminopyrazoles as fgfr inhibitors | |
| TNSN08369A1 (en) | Benzimidazole derivatives | |
| WO2007131907A3 (en) | 1h-indol-5-yl-piperazin-1-yl-methanone derivatives | |
| DE602006002608D1 (de) | 4-phenyl-5-oxo-l,4,5,6,7,8-hexahydrochinolin-derivate als arzneimittel zur behandlung von unfruchtbarkeit |